$IBIO
-
Markets
Ibio Unveils Promising Data For IBIO-600 And Activin E Antibody, Enhancing Cardiometabolic And Obesity Treatment Options
$IBIO IBio, Inc. (Nasdaq:IBIO) has recently shared compelling data from its latest pharmacokinetics study on IBIO-600, a novel long-acting anti-myostatin…
Read More »